Source - RNS
RNS Number : 0404K
Horizon Discovery Group plc
06 April 2018
 

Horizon Discovery Group plc 

 

Director/PDMR Shareholding

 

Cambridge, UK, 6 April 2018: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or the "Company"), a global leader in gene editing and gene modulation technologies, today announces that Mr Richard Vellacott, Interim Chief Executive Officer and Chief Financial Officer of the Company, and Dr Jonathan Milner, Non-Executive Director of the Company, have purchased ordinary shares of 1.0p each in the capital of the Company ("Ordinary Shares"). Details of these purchases of Ordinary Shares, and each Director's resulting beneficial interest in the Company's issued share capital, are shown below:

 

Name of Director

Number of Ordinary Shares purchased

Average purchase price per share (pence)

Resulting number of Ordinary Shares held

Resulting number of Ordinary Shares held as a percentage of the Company's issued share capital

 

Mr Richard Vellacott

37,830

131.5

75,699

0.051%

Dr Jonathan Milner*

 370,000

132

10,815,172

7.25%

 

*Dr Milner's purchase of Ordinary Shares was made by his wife (Mrs Roza Gounari) and is therefore considered a beneficial holding of Dr Milner's.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Mr Richard Vellacott

2

Reason for the notification

a)

Position/status

Executive Director

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Horizon Discovery Group plc

b)

Legal Entity Identifier

213800L812B9NI5M3G89

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1.0p each

 

 

 

GB00BK8FL363

b)

Nature of the transaction

Purchase of shares

 

c)

Currency

GBP

d)

Price(s) and volume(s)

Average Price(s)

Volume(s)

131.5p

37,830

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

37,830

131.5p

£49,746.45

f)

Date of the transaction

5 April 2018

g)

Place of the transaction

London Stock Exchange, AIM

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Dr Jonathan Milner

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Horizon Discovery Group plc

b)

Legal Entity Identifier

213800L812B9NI5M3G89

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1.0p each

 

 

 

GB00BK8FL363

b)

Nature of the transaction

Purchase of shares

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

132p

370,000


e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

370,000

132p

£490,575.40

f)

Date of the transaction

5 April 2018

g)

Place of the transaction

London Stock Exchange, AIM

 

 

- ENDS -

 

For further information from Horizon Discovery Group plc, please contact:

 

Horizon Discovery Group plc

Richard Vellacott, Interim Chief Executive Officer and Chief Financial Officer

Chris Claxton, VP Investor Relations

Tel: +44 (0) 1223 655 580

 

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: +44 (0) 20 3709 5701

Email: [email protected]

 

Numis Securities Limited (Broker and NOMAD)

Michael Meade / Freddie Barnfield

Tel: +44 (0) 207 260 1000

 

About Horizon Discovery Group plc www.horizondiscovery.com

Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon delivers inspired cell solutions using its translational genomics platform, a highly precise and flexible suite of DNA editing (rAAV, ZFN, CRISPR and Transposon) and modulation (RNAi, cDNA and ORF) tools for research and clinical applications that advance human health. Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell lines.

Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalized molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company's own R&D pipeline.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD".

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHFELLBVZFXBBX